NOTESKARTS.COM

BP804ET

PHARMACEUTICAL REGULATORY SCIENCE

| B.Pharm 8th Semester

UNIT - I

NEW DRUG DISCOVERY AND DEVELOPMENT

SYLLABUS COVERAGE

Topics Covered: Stages of drug discovery | Drug development process | Pre-clinical studies | Non-clinical activities | Clinical studies | Innovator and Generics | Concept of Generics | Generic Drug Product Development

Introduction to Drug Discovery and Development

Drug discovery and development is a complex, multi-stage scientific process that involves identifying a new chemical entity (NCE) or new biological entity (NBE) with therapeutic potential and transforming it into a safe, effective, and commercially viable pharmaceutical product. The entire process, from initial discovery to market approval, typically takes 10-15 years and costs approximately $1-2 billion.

> *The ultimate goal of drug discovery is to identify new medicines that can prevent, diagnose, or treat diseases with an acceptable safety and efficacy profile.*

Overview of the Drug Development Pipeline

The drug development process can be broadly categorized into the following stages:

1. Target Identification and Validation
2. Hit Discovery and Lead Identification
3. Lead Optimization
4. Pre-clinical Development
5. Clinical Trials (Phase I, II, III)
6. Regulatory Submission and Approval
7. Post-marketing Surveillance (Phase IV)

Stages of Drug Discovery

Drug discovery encompasses all activities from the initial identification of a therapeutic target to the selection of a candidate molecule for development. It involves multiple stages, each designed to progressively narrow down thousands of compounds to one or a few promising candidates.

Target Identification

Target identification is the process of identifying a biological molecule (usually a protein) that plays a crucial role in a disease and can be modulated by a drug to produce a desired therapeutic effect.

- **Definition:** A drug target is a molecular site in the body, usually a protein such as a receptor, enzyme, ion channel, or nucleic acid, with which a drug interacts to produce its pharmacological effect.
- **Sources of Targets:** Genomics, proteomics, metabolomics, disease biology, literature review, and bioinformatics.
- **Types of Targets:** Receptors (GPCRs, nuclear receptors), Enzymes (kinases, proteases), Ion channels, Transporters, DNA/RNA
- **Methods:** Genomic screening, GWAS (Genome-Wide Association Studies), knockout models, RNAi studies

Target Validation

Once a potential target is identified, it must be validated to confirm that modulation of the target produces the desired therapeutic outcome.

- Genetic validation: Using knockout/knockin animal models
- Pharmacological validation: Using known compounds to modulate the target

- Clinical validation: Evidence from human genetic studies or biomarkers
- Biochemical validation: In vitro assays demonstrating target modulation

Point: A validated target reduces the risk of late-stage failures by confirming that the target is biologically relevant and that its modulation leads to the desired pharmacological effect.

Hit Identification (Hit Discovery)

Hit discovery involves screening large chemical libraries to identify compounds (hits) that interact with the validated target and show initial biological activity.

High-Throughput Screening (HTS)

- Automated screening of thousands to millions of compounds against a target
- Uses miniaturized assays (96-well, 384-well, 1536-well plates)
- Can screen 100,000 to 1,000,000 compounds per day
- Includes biochemical assays, cell-based assays, and functional assays

Virtual Screening / In Silico Screening

- Computer-based screening of virtual compound libraries
- Techniques: Molecular docking, pharmacophore modeling, QSAR
- Cost-effective approach - filters millions of virtual compounds before synthesis

Fragment-Based Drug Discovery (FBDD)

- Screening of small chemical fragments (MW < 300 Da)
- Fragments are grown or linked to create lead compounds
- Uses biophysical techniques: NMR, X-ray crystallography, SPR

Natural Product Screening

- Screening of natural products (plants, microorganisms, marine organisms)
- Many successful drugs derived from natural sources (e.g., penicillin, morphine, taxol)

Lead Identification and Selection

A hit becomes a lead when it fulfills defined criteria of potency, selectivity, and drug-likeness. Lead compounds are further evaluated to confirm activity and assess preliminary ADME (Absorption, Distribution, Metabolism, Excretion) properties.

Criteria	Hit Compound	Lead Compound
Potency (IC50/EC50)	< 10 µM	< 1 µM
Selectivity	Basic selectivity	Good selectivity
MW (Lipinski)	< 500 Da (preferred)	< 500 Da
LogP	Assessed	1-3 (preferred)
Solubility	Checked	Adequate (>50 µg/mL)
Toxicity	Not determined	Low cytotoxicity
Structure	Confirmed	Confirmed, patentable

Lead Optimization

Lead optimization is the iterative process of chemically modifying the lead compound to improve its drug-like properties while maintaining or enhancing its potency and selectivity against the target.

- **Objectives:** Improve potency and selectivity, optimize ADME properties, reduce toxicity, enhance metabolic stability, improve bioavailability
- **Medicinal Chemistry Strategies:** Structure-Activity Relationship (SAR) studies, bioisosterism, prodrug approach, scaffold hopping
- **Tools Used:** Computational modeling, QSAR, X-ray crystallography, NMR, in vitro ADME assays

Lipinski's Rule of Five (Ro5)

Developed by Christopher Lipinski (1997), this rule predicts oral bioavailability:

- Molecular Weight (MW) $\leq$ 500 Da
- Hydrogen Bond Donors (HBD) $\leq$ 5
- Hydrogen Bond Acceptors (HBA) $\leq$ 10
- LogP (lipophilicity) $\leq$ 5
- Polar Surface Area (PSA) $\leq$ 140 A^2

Note: Compounds violating more than one of these rules are likely to have poor oral bioavailability. Exceptions include natural products and compounds that are substrates for transporters.

Candidate Drug Selection

After lead optimization, the best compound is selected as the 'Candidate Drug' or 'Development Candidate' for formal pre-clinical and clinical testing. This compound must demonstrate:

- High potency and selectivity against the target
- Acceptable safety profile in preliminary toxicity studies
- Suitable pharmacokinetic (PK) properties (oral bioavailability, half-life, etc.)
- Chemical stability and patentability
- Feasible synthetic route for scale-up

Drug Development Process

Drug development is the process of bringing a candidate drug through pre-clinical testing, clinical trials, regulatory review, and ultimately to market. It is a highly regulated, resource-intensive process governed by national and international regulatory guidelines.

Stage	Activities	Duration
Discovery	Target ID, HTS, lead optimization	2-5 years
Pre-clinical	In vitro/in vivo studies, toxicology, formulation	1-3 years
Phase I Clinical	Safety, tolerability, PK in healthy volunteers	1-2 years
Phase II Clinical	Efficacy, dose finding in patients	2-3 years
Phase III Clinical	Large-scale efficacy and safety confirmation	3-5 years

Regulatory Review	NDA/IND submission, agency review	1-2 years
Post-marketing (IV)	Long-term safety surveillance	Ongoing

Investigational New Drug (IND) Application

Before initiating clinical trials in humans, the sponsor must file an IND application with the regulatory authority (e.g., USFDA, CDSCO in India). The IND application includes:

- Animal pharmacology and toxicology data
- Manufacturing information (Chemistry, Manufacturing, and Controls - CMC)
- Clinical protocols (study design, endpoints, patient population)
- Investigator information and qualifications
- Commitments to obtain informed consent from subjects

In India: The IND equivalent is the 'Permission to Conduct Clinical Trials' from the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940.

Pre-clinical Studies

Pre-clinical studies are laboratory and animal studies conducted before human trials to evaluate the safety and biological activity of a candidate drug. These studies are performed in compliance with Good Laboratory Practice (GLP) guidelines.

> *Pre-clinical studies aim to determine if the drug candidate is reasonably safe to test in humans and to provide initial data on its biological activity, mechanism of action, and potential toxicity.*

In Vitro Studies

In vitro studies are conducted outside a living organism, using cells, tissues, or biochemical preparations in controlled laboratory conditions.

- **Pharmacological Activity:** Receptor binding assays, enzyme inhibition assays, cell-based functional assays
- **ADME Studies:** Caco-2 cell permeability (absorption), plasma protein binding, microsomal stability (metabolism), P-glycoprotein substrate studies
- **Genotoxicity:** Ames test (bacterial reverse mutation), in vitro chromosomal aberration assay, mouse lymphoma assay
- **Cytotoxicity:** MTT assay, LDH release assay on various cell lines

In Vivo Pharmacological Studies

These studies evaluate the drug's pharmacological activity and mechanism of action in animal models of disease.

- Proof-of-concept studies in animal disease models
- Dose-response relationship determination
- Comparison with standard reference drugs
- Pharmacokinetic (PK) studies: absorption, distribution, metabolism, excretion in animals
- Pharmacodynamic (PD) studies: onset, duration, and intensity of action

Toxicological Studies

Toxicology studies assess the potential harmful effects of the drug candidate. These are the most comprehensive and time-consuming pre-clinical studies.

Acute Toxicity

- Single dose administered by intended clinical route and at least one additional route
- Determines the Lethal Dose 50% (LD50) - dose killing 50% of test animals
- Animals observed for 14 days after dosing
- Identifies target organs of toxicity
- Species: Rodents (rat, mouse); required in 2 species typically

Sub-acute / Sub-chronic Toxicity

- Repeated dose studies for 14-90 days duration
- Identifies No Observed Adverse Effect Level (NOAEL)
- Determines Lowest Observed Adverse Effect Level (LOAEL)
- Evaluates hematology, biochemistry, organ weights, histopathology

Chronic Toxicity

- Repeated dose studies for 6-12 months or lifetime
- Required for drugs intended for long-term human use
- Evaluates cumulative toxicity and reversibility
- Includes carcinogenicity assessment in rodents (2-year studies)

Reproductive and Developmental Toxicity

- Fertility and general reproductive performance studies (Segment I)
- Embryo-fetal development (teratology) studies (Segment II)
- Peri/postnatal development studies (Segment III)
- Critical for evaluating drug safety in pregnancy

Genotoxicity Studies

- Ames test (Salmonella reverse mutation assay)
- In vitro mammalian chromosomal aberration test
- In vivo mouse bone marrow micronucleus test
- Evaluates potential to cause DNA damage or mutations

Carcinogenicity Studies

- Required for drugs intended for chronic use (>6 months) in humans
- Long-term rodent studies (rats and mice, 2 years)
- Evaluated for tumor incidence, type, and location
- Alternative: transgenic mouse models (p53+/-, rasH2) for 6-month studies

Type of Toxicity Study	Duration	Species	Route
Acute toxicity	Single dose, 14d obs.	Rodent + non-rodent	Oral, IV, intended route
Sub-acute toxicity	14-28 days	Rodent + non-rodent	Intended clinical route
Sub-chronic toxicity	90 days	Rodent + non-rodent	Intended clinical route

Chronic toxicity	6-12 months	Rodent + non-rodent	Intended clinical route
Carcinogenicity	24 months	Rat + mouse	Dietary/gavage
Reproductive tox.	Segment I, II, III	Rat (rabbit for Seg II)	Intended clinical route
Genotoxicity	In vitro + in vivo	Salmonella, mammalian cells	Various

Safety Pharmacology Studies

Safety pharmacology studies assess potential adverse pharmacodynamic effects on vital organ systems (CNS, cardiovascular, and respiratory systems) at exposures in the therapeutic range and above.

- CNS: Motor activity, behavior, coordination (Irwin battery)
- Cardiovascular: Blood pressure, heart rate, ECG (especially QT interval - hERG assay)
- Respiratory: Respiratory rate, tidal volume, arterial blood gases
- Renal: Urine output, electrolytes, GFR

Formulation Development (Pre-clinical)

- Selection of suitable dosage form for clinical studies
- Solubility and dissolution studies
- Compatibility studies with excipients
- Stability studies (ICH guidelines)
- Development of analytical methods for drug substance and product

Non-Clinical Activities

Non-clinical activities encompass all studies conducted outside of human subjects to support drug development. While 'pre-clinical' studies refer specifically to studies before first-in-human (FIH) trials, 'non-clinical' activities extend throughout the development lifecycle, including studies conducted to support later phase clinical trials or post-approval needs.

Chemistry, Manufacturing and Controls (CMC)

CMC activities form a critical part of non-clinical development and cover:

Drug Substance (API) Development

- Chemical characterization: structure elucidation (NMR, IR, MS, X-ray crystallography)
- Physicochemical properties: solubility, particle size, polymorphism, hygroscopicity
- Synthetic route development and optimization
- Process scale-up and process validation
- Impurity identification and qualification (ICH Q3A)
- Reference standard establishment

Drug Product Formulation Development

- Selection and justification of dosage form
- Excipient selection and compatibility studies
- Formulation optimization (Design of Experiments - DoE)
- Analytical method development and validation (ICH Q2)

- Stability studies per ICH Q1A - accelerated and long-term

ADME/Pharmacokinetic Studies

Detailed pharmacokinetic studies characterize how the body handles the drug and help in the design of clinical dosing regimens.

ADME Parameter	Studies	Relevance
Absorption	In vitro permeability (Caco-2), oral bioavailability in animals	Predicts human absorption
Distribution	Volume of distribution, plasma protein binding, tissue distribution	Predicts drug exposure at target
Metabolism	CYP enzyme studies, metabolite ID, in vitro/in vivo correlation	Predicts drug interactions, metabolite safety
Excretion	Mass balance, urinary/fecal/biliary excretion, enterohepatic circulation	Predicts elimination and dosing frequency
Drug Interactions	CYP inhibition/induction, transporter studies (P-gp, BCRP)	Risk of DDIs in clinical use

Analytical Method Development and Validation

- Development of bioanalytical methods for quantification of drug and metabolites in biological matrices
- Validation per ICH Q2(R1): specificity, linearity, accuracy, precision, LOD, LOQ, robustness
- Quality control (QC) samples for in-study monitoring

Regulatory Strategy (Non-clinical)

- Preparation of pre-IND meeting requests
- Consultation with regulatory agencies (FDA, EMA, CDSCO)
- Gap analysis against current regulatory guidelines (ICH M3, S1-S9)
- Preparation of non-clinical overview and study reports for regulatory submissions

ICH Guidelines Governing Non-clinical Studies

ICH Guideline	Subject
ICH S1A-S1C	Carcinogenicity studies
ICH S2(R1)	Genotoxicity studies
ICH S3A-S3B	Pharmacokinetic studies
ICH S4	Chronic toxicity testing
ICH S5(R3)	Reproductive toxicology
ICH S6	Biotechnology-derived pharmaceuticals
ICH S7A-S7B	Safety pharmacology (S7B: QT/hERG)
ICH S8	Immunotoxicity studies

ICH S9	Nonclinical evaluation of anticancer drugs
ICH M3(R2)	Timing of non-clinical studies relative to clinical

Clinical Studies

Clinical studies (clinical trials) are systematic investigations conducted in human subjects to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of a drug under investigation. They are regulated by the Declaration of Helsinki, ICH E6 GCP guidelines, and national drug regulatory acts.

Phases of Clinical Trials

Phase I Clinical Trials (First-in-Human Studies)

Subjects	20-100 healthy volunteers (occasionally patients in oncology/HIV)
Objectives	Assess safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD)
Design	Open-label, dose-escalation studies (Single Ascending Dose - SAD; Multiple Ascending Dose - MAD)
Duration	1-2 years
Endpoints	Safety, PK parameters (Cmax, Tmax, AUC, t1/2, CL, Vd), MTD, dose-limiting toxicities (DLTs)
Studies	First-in-human (FIH), food effect study, QTc study, drug interaction studies, mass balance study

Phase II Clinical Trials (Proof of Concept / Dose Finding)

Subjects	100-500 patients with the target disease
Objectives	Evaluate preliminary efficacy, determine optimal dose, further assess safety and tolerability
Sub-phases	Phase IIa: Proof-of-concept (POC); Phase IIb: Dose-finding/ranging
Design	Randomized, controlled (placebo or active comparator), often double-blind
Duration	2-3 years
Endpoints	Biomarkers, surrogate endpoints, preliminary clinical efficacy, dose-response relationship

Phase III Clinical Trials (Pivotal Trials)

Subjects	1,000-5,000+ patients across multiple centers and countries
Objectives	Confirm efficacy and safety, compare with existing standard treatment, generate data for regulatory submission
Design	Randomized, double-blind, placebo-controlled or active-controlled, multi-center trials

Duration	3-5 years
Endpoints	Primary clinical endpoints (mortality, morbidity, cure rates), safety database
Outcome	Data form the basis of New Drug Application (NDA) or Marketing Authorization Application (MAA)

Phase IV Clinical Trials (Post-Marketing Surveillance)

- Conducted after marketing approval of the drug
- Objectives: Long-term safety monitoring, detection of rare adverse effects, new indications, pharmacoeconomic evaluation
- Includes pharmacovigilance (PV) activities
- May lead to label updates, restrictions, or withdrawal from market
- Example: Rofecoxib (Vioxx) withdrawn post-Phase IV due to cardiovascular risks

Good Clinical Practice (GCP)

GCP (ICH E6) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects.

Principles:

- Protection of the rights, safety, and well-being of trial subjects
- Informed consent: voluntary, documented, prior to participation
- Independent Ethics Committee (IEC) / Institutional Review Board (IRB) approval
- Qualified investigators and adequate trial facilities
- Data integrity: accurate, complete, legible, traceable records
- Sponsor oversight including monitoring, auditing, and SOPs

Clinical Trial Design Elements

Design Element	Description
Randomization	Random allocation of subjects to treatment groups to eliminate selection bias
Blinding	Single-blind (patient), double-blind (patient + investigator), triple-blind (+ statistician)
Control Groups	Placebo, active comparator, dose-response, historical control
Crossover Design	Subject receives both treatments sequentially with washout period
Parallel Design	Different groups receive different treatments simultaneously
Adaptive Design	Protocol modifications based on interim data (e.g., sample size re-estimation)
Factorial Design	Tests multiple interventions simultaneously
Stratification	Randomization within subgroups (strata) to ensure balance

Regulatory Submissions Based on Clinical Data

- **NDA (New Drug Application):** Submitted to USFDA for approval of new chemical entity
- **MAA (Marketing Authorization Application):** Submitted to EMA (European Medicines Agency)

- **NDA in India:** Submitted to CDSCO under the New Drugs and Clinical Trials Rules, 2019
- **BLA (Biologics License Application):** For biological drug products in the US

Innovator and Generics

Innovator Drug Products

An innovator drug (also called brand-name drug or reference listed drug - RLD) is a pharmaceutical product that was first approved based on a complete pre-clinical and clinical data package, supported by an original NDA or equivalent regulatory submission.

- **Definition:** The original drug product developed by the originator company after investing in all stages of discovery, development, and clinical trials.
- **Characteristics:** Extensive clinical trial data, patent protection (typically 20 years from filing), higher cost, brand name, first to market
- **Examples:** Lipitor (atorvastatin) by Pfizer, Viagra (sildenafil) by Pfizer, Gleevec (imatinib) by Novartis

Concept of Generic Drugs

A generic drug is a pharmaceutical product that is bioequivalent to the innovator (reference) drug product in dosage form, strength, route of administration, quality, performance characteristics, and intended use.

> *Generic drugs do NOT require the sponsor to repeat extensive pre-clinical and clinical trials - they rely on the safety and efficacy data already established for the innovator product.*

Regulatory Definition (USFDA)

According to the US FDA (21 CFR 314.3), a generic drug is a drug product that:

- Contains the same active ingredient(s) as the innovator drug
- Is identical in strength, dosage form, and route of administration
- Has the same labeling (with minor permissible differences)
- Is manufactured under Good Manufacturing Practice (GMP) standards
- Demonstrates bioequivalence to the reference listed drug (RLD)

Definition in India (Schedule Y / NDC Rules 2019)

In India, as per the New Drugs and Clinical Trials Rules, 2019 and the Drugs and Cosmetics Act, 1940:

- A generic drug must contain the same active pharmaceutical ingredient (API) as the innovator
- Must demonstrate pharmaceutical equivalence and bioequivalence
- Approved via Abbreviated New Drug Application (ANDA) process through CDSCO

Comparison: Innovator vs Generic Drug

Parameter	Innovator Drug	Generic Drug
Approval Pathway	Full NDA/MAA with complete data	ANDA - abbreviated (bioequivalence only)

Development Cost	~$1-2 billion	~$1-5 million
Development Time	10-15 years	2-5 years
Data Required	Full pre-clinical + clinical data	Bioequivalence + pharmaceutical equivalence
Patent Protection	Yes (20 years from filing)	No (files after patent expiry/challenge)
Price	Higher (recovery of R&D investment)	60-80% lower than innovator
Market Entry	First to market	After patent expiry or paragraph IV challenge
Clinical Trials	Required (all phases)	Generally not required
Brand Name	Proprietary brand name	INN (generic name) or different brand
Inactive Ingredients	Innovator's formulation	May differ (must not affect BE)

Patent System and Market Exclusivity

Patent protection allows innovator companies to recover their R&D investment before generic competition enters the market.

- **Patent Term:** 20 years from the date of filing the patent application
- **Patent Restoration:** Hatch-Waxman Act (USA) allows restoration of patent term lost during regulatory review (up to 5 years, max 14 years remaining)
- **Data Exclusivity:** Innovator's clinical data is protected from use by generic applicants for a defined period (e.g., 5 years for NCEs in USA; 8 years in EU)
- **Paragraph IV Challenge:** Generic companies can challenge an innovator's patent before expiry under Hatch-Waxman provisions; first successful filer gets 180-day exclusivity
- **India:** Section 3(d) of the Indian Patents Act prevents evergreening of patents for known substances without significant enhancement of efficacy

Generic Drug Product Development

Generic drug product development involves the systematic development of a pharmaceutical product that is equivalent to the innovator/reference product, demonstrating pharmaceutical equivalence and bioequivalence. It is a regulated process culminating in an Abbreviated New Drug Application (ANDA) submission.

Concepts in Generic Development

Pharmaceutical Equivalence

Two drug products are pharmaceutical equivalents if they:

- Contain the same active ingredient(s) in the same amount
- Have the same dosage form and route of administration
- Meet the same or comparable standards (identity, strength, quality, purity)
- May differ in: inactive ingredients (excipients), shape, color, labeling, and packaging

Bioequivalence (BE)

Bioequivalence is the absence of a significant difference in the rate and extent of absorption of the active ingredient from two pharmaceutical equivalents when administered at the same molar dose under similar conditions.

USFDA Standard: Two products are bioequivalent if the 90% Confidence Interval (CI) of the geometric mean ratio (Test/Reference) for AUC and Cmax falls within 80.00% to 125.00%.

- **AUC (Area Under Curve):** Measures extent of absorption (bioavailability)
- **Cmax (Peak concentration):** Measures rate of absorption
- **Tmax (Time to peak):** Informational; not part of BE limits

Therapeutic Equivalence

Two drug products are therapeutically equivalent if they are:

- Pharmaceutically equivalent AND
- Bioequivalent AND
- Labeled appropriately AND
- Manufactured in compliance with GMP

Abbreviated New Drug Application (ANDA)

The ANDA (or its equivalent) is the regulatory pathway through which a generic drug product is approved without submitting full pre-clinical and clinical data, by demonstrating that the generic product is bioequivalent to the approved innovator (RLD).

ANDA Requirements (USFDA, 21 CFR Part 314)

- Bioequivalence data (in vivo and/or in vitro)
- Pharmaceutical equivalence demonstration
- Labeling same as RLD (with permissible differences)
- Chemistry, Manufacturing, and Controls (CMC) information
- GMP certification
- Patent certification (Paragraph I, II, III, or IV)
- Environmental impact assessment

ANDA Equivalent in India

- In India, approval for generic drugs is obtained from CDSCO via Form 44 (for permission to manufacture)
- Bioequivalence data required for systemic generic products per CDSCO Bioequivalence Guidelines (2005 and updated 2020 draft)
- Generic approval falls under Rule 122B and Rule 122E of the Drugs and Cosmetics Rules, 1945

Steps in Generic Drug Product Development

Step	Activities

1. Target Product Profile (TPP)	Define dosage form, strength, route, release mechanism based on innovator product
2. API Sourcing and Characterization	Identify API source, characterize physicochemical properties, assess polymorphism, particle size
3. Reference Product Study	Procurement of RLD, dissolution profile analysis (pH 1.2, 4.5, 6.8), in vitro characterization
4. Formulation Development	Develop formulation using QbD (Quality by Design), design space exploration, DoE studies
5. In vitro Dissolution Matching	Match dissolution profile of generic to RLD at multiple pH values (f2 similarity factor ≥ 50)
6. Analytical Method Development	Develop and validate HPLC methods for assay, dissolution, impurity testing
7. Stability Studies	Conduct accelerated (40°C/75%RH, 6 months) and long-term (25°C/60%RH, 12 months) stability per ICH Q1
8. Pilot Batch Manufacturing	Manufacture at 1/10th of production scale or 100,000 units minimum (USFDA)
9. Bioequivalence Study	Conduct in vivo BE study in healthy adult subjects under fasting and fed conditions
10. Scale-up and Validation	Full-scale manufacturing, process validation (IQ, OQ, PQ), cleaning validation
11. ANDA Preparation and Submission	Compile all data in CTD format; submit to regulatory authority
12. Regulatory Review and Approval	Agency review (USFDA ~10-12 months; CDSCO ~12-18 months), queries, approval

Biopharmaceutics Classification System (BCS)

The BCS classifies drugs based on their aqueous solubility and intestinal permeability. It helps in predicting in vivo drug behavior and determines if an in vivo bioequivalence study can be waived (biowaiver).

BCS Class	Solubility	Permeability	In Vivo BE Concern	Biowaiver
Class I	High	High	Low (if rapid dissolution)	Yes (IR solid oral)
Class II	Low	High	Yes - dissolution limited	Limited
Class III	High	Low	Yes - permeability limited	Yes (rapid dissolution)
Class IV	Low	Low	Yes - both concerns	Not recommended

Biowaiver: A biowaiver allows waiving of in vivo BE study based on in vitro dissolution data. BCS Class I drugs with rapidly dissolving formulations (≥85% dissolved in 30 min at pH 1.2, 4.5, 6.8) may qualify for biowaiver.

Bioequivalence Study Design

In vivo bioequivalence studies are typically single-dose, two-treatment, two-period, two-sequence crossover studies in healthy adult volunteers.

- **Study Design:** Randomized, open-label, two-treatment, two-period, two-sequence crossover (2x2 crossover)
- **Subjects:** Minimum 12-24 healthy adult volunteers (both fasting and fed studies if applicable)
- **Sampling:** Multiple blood samples at pre-specified time points post-dose
- **Washout Period:** At least 5 half-lives between periods to avoid carry-over
- **PK Parameters:** AUC0-t, AUC0-inf, Cmax, Tmax, t1/2, Kel
- **Statistical Analysis:** ANOVA on log-transformed data; 90% CI for AUC and Cmax must be within 80-125%

Quality by Design (QbD) in Generic Development

QbD is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management (ICH Q8, Q9, Q10).

- **Quality Target Product Profile (QTPP):** Defines desired quality characteristics of the final product
- **Critical Quality Attributes (CQA):** Physical, chemical, biological properties critical to product quality
- **Critical Material Attributes (CMA):** Properties of API and excipients affecting CQAs
- **Critical Process Parameters (CPP):** Process parameters affecting CQAs
- **Design Space:** Multidimensional combination of input variables within which quality is assured
- **Control Strategy:** Planned set of controls ensuring process performance and product quality

Scale-Up and Post-Approval Changes (SUPAC)

SUPAC guidelines (USFDA) provide recommendations for changes to the formulation, manufacturing site, or scale after regulatory approval:

- SUPAC-IR: Immediate Release solid oral dosage forms
- SUPAC-MR: Modified Release solid oral dosage forms
- SUPAC-SS: Semisolid dosage forms
- Level 1 change (minor): usually notification only
- Level 2 change (moderate): requires additional dissolution data
- Level 3 change (major): requires in vivo BE study

— Best Of Luck For Your Exam —

—PHARMACEUTICAL REGULATORY SCIENCE —

www.noteskarts.com | B.Pharm 8th Semester | As per PCI/AKTU Syllabus